David L. Spector

This study identifies PTP1B as a survival dependency in trastuzumab-resistant HER2-positive breast cancer, showing it regulates CFL1 and HSP90a abundance through dephosphorylation.

This study shows that daraxonrasib, a pan-RAS(on) inhibitor, effectively inhibits TNBC cell proliferation and tumor growth, either alone or in combination with a MEK inhibitor.

This study evaluates MALAT1-targeting ASOs in breast cancer using patient-derived organoid models, showing MALAT1's role in alternative splicing, metastasis, and tumor-stroma interactions.

The paper identifies a subset of actively transcribed genes associated with Lamin B1 at the nuclear envelope in mESCs, showing enrichment of guanine and cytosine in their gene bodies and promoters.

This study shows CDK11 is critical for cancer cell survival and identifies 1p36 deletions as a biomarker for CDK11 inhibitor sensitivity, but on-target toxicity limits therapeutic efficacy.

This study quantifies kinase protein abundance in human tissues using proteomic mass spectrometry, revealing heterogeneity in breast cancer subtypes and enabling clinical applications.

This study identifies MARK2/3 as essential kinases for YAP/TAZ function in cancer and shows their inhibition can restore Hippo pathway tumor suppression.

The paper identifies MED12-p63 interaction as a driver of basal identity in PDAC through genetic screens and biochemical analysis.

The paper investigates allele-specific regulation of monoallelically expressed autosomal genes in cardiac lineage cells, finding maternal allele dominance in cardiac development and homeostasis.

This study identifies Platr4 as an ESC-specific lncRNA that regulates meso/endoderm lineage commitment by interacting with Tead4 to control Ctgf expression, leading to cardiac defects in knockout mice.

This study uses long-read sequencing to identify structural variants in breast cancer genomes, showing high accuracy and sensitivity compared to short-read methods.